Clinical Report: Aptamer-Functionalized Contact Lenses for Drug Delivery
Overview
Aptamer-functionalized contact lenses represent a novel approach to ocular drug delivery, enhancing drug residence time and targeting specificity. This technology could transform the management of chronic ocular diseases by integrating drug delivery with biosensing capabilities.
Background
Delivering drugs to the eye is challenging due to rapid clearance mechanisms that limit bioavailability. Traditional methods, such as eye drops, often result in less than 5% of the drug reaching the target tissues. Aptamers, with their high specificity and low immunogenicity, offer a promising solution for improving ocular drug delivery through innovative platforms like contact lenses.
Data Highlights
No numerical data provided in the source material.
Key Findings
- Aptamers can be integrated into contact lenses to enhance drug delivery efficiency.
- Two FDA-approved anti-VEGF aptamers have set a precedent for aptamer use in ocular therapies.
- Aptamer-functionalized hydrogels show potential for controlled drug delivery in chronic ocular diseases.
- Continuous monitoring of ocular conditions may be possible through biosensor integration in contact lenses.
- Challenges remain regarding aptamer stability, lens comfort, and regulatory compliance for clinical use.
Clinical Implications
The integration of aptamers into contact lenses could significantly improve the management of ocular diseases by providing targeted and sustained drug delivery. Additionally, the potential for real-time monitoring of ocular conditions may enhance patient outcomes and facilitate timely interventions.
Conclusion
Aptamer-functionalized contact lenses hold transformative potential for ocular drug delivery and diagnostics, though further research is needed to address existing challenges before clinical implementation.
References
- Pelusi L, Mandatori D, Mastropasqua L, et al., Pharmaceutics, 2023 -- Innovation in the development of synthetic and natural ocular drug delivery systems for eye diseases treatment
- Santarpia G, Carnes E, Int J Mol Sci, 2024 -- Therapeutic applications of aptamers
- Bege M, Ghanem Kattoub R, Borbás A, Pharmaceutics, 2025 -- The 20th anniversary of pegaptanib (MacugenTM), the first approved aptamer medicine
- Liu J, Ren Z, Sun Y, et al., ACS Nano, 2023 -- Investigation of the relationship between aptamers’ targeting functions and human plasma proteins
- Abune L, Davis B, Wang Y, Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2021 -- Aptamer-functionalized hydrogels: An emerging class of biomaterials
- Wong K-Y, Liu Y, Zhou L, Wong M-S, Liu J, Pharmaceutics, 2024 -- Mucin-targeting-aptamer functionalized liposomes for delivery of cyclosporin A
- Contact Lens Spectrum — FAST FORWARD TO THE FUTURE
- Contact Lens Spectrum — Fast Forward to the Future: Contact Lens Microfluidics
- contact lens spectrum — Fast Forward to the Future: Contact Lens Microfluidics
- contact lens spectrum — Fast Forward to the Future: Personalized Contact Lenses in One Shot
- Contact Lens Spectrum — FAST FORWARD TO THE FUTURE
- AAO Conjunctivitis Guideline Summary 2024 Preferred Practice Pattern
- These highlights do not include all the information needed to use ACUVUE® THERAVISION™ WITH KETOTIFEN safely and effectively. See full prescribing information for ACUVUE® THERAVISION™ WITH KETOTIFEN. ACUVUE® THERAVISION™ WITH KETOTIFEN (etafilcon A drug-eluting contact lens with ketotifen), for ophthalmic use Initial U.S. Approval: 2022
- Recent Developments in Aptamer-Based Sensors for Diagnostics
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
